Tirzepatide (Mounjaro / Zepbound)

What it is

Tirzepatide is the first dual GIP + GLP-1 receptor agonist — it activates two gut-hormone (incretin) receptors at once, whereas semaglutide (Ozempic/Wegovy) hits only GLP-1. It's a once-weekly injection. The exact same molecule is sold as Mounjaro for type 2 diabetes (FDA-approved May 13, 2022, NDA 215866) and Zepbound for obesity (FDA-approved November 8, 2023, NDA 217806); Zepbound later added an obstructive sleep apnea indication (December 20, 2024), the first drug ever approved for OSA. (All three dates verified July 2026 against the primary FDA approval letters / FDA press releases.) (Mounjaro approval letter, NDA 215866; Zepbound approval letter, NDA 217806; FDA — first drug for OSA, Dec 20 2024)

We include tirzepatide in this library on purpose. Most entries here describe peptides with thin or absent human evidence. This one is the opposite — and the contrast is the most useful thing a reader can learn about the whole space.

What humans actually show

This is what a strong evidence base looks like:

• SURMOUNT-1 (obesity, no diabetes): 72-week, double-blind, placebo-controlled RCT, N=2,539. Mean weight change at week 72: −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs. −3.1% placebo. 57% of the 15 mg group lost at least 20% of body weight, vs. 3% on placebo. (Jastreboff et al., NEJM 2022)
• Note on the "22.5%" you'll see in headlines: that figure comes from a completer/on-treatment analysis. The peer-reviewed intention-to-treat number at 15 mg is −20.9%. Both are real; they answer slightly different questions.
• SURPASS-2 (type 2 diabetes, head-to-head vs. semaglutide 1 mg): 40-week RCT, N=1,879. Tirzepatide beat semaglutide on both blood sugar and weight at every dose. (NEJM 2021)
• SURMOUNT-5 (obesity, direct head-to-head vs. semaglutide/Wegovy): 72-week RCT, N=751. Tirzepatide −20.2% vs. semaglutide −13.7% — a ~6.5-percentage-point advantage, p<0.001. (Aronne et al., NEJM 2025)
• SURMOUNT-OSA (obstructive sleep apnea + obesity): two 52-week RCTs; a large share of treated participants met criteria for disease resolution. Supported a subsequent FDA sleep-apnea indication for Zepbound. (NEJM 2024)
• Cardiovascular: SURPASS-CVOT (type 2 diabetes + established atherosclerotic CV disease; ~13,000 randomized, tirzepatide vs. dulaglutide, median ~4-yr follow-up) met its primary endpoint of non-inferiority on 3-point MACE (CV death, MI, stroke) — it was not shown superior on the primary endpoint. Reported topline: roughly an 8% relative reduction in 3-point MACE and ~16% lower all-cause mortality favoring tirzepatide numerically, with an expanded MACE endpoint reaching significance. Published NEJM, December 17, 2025. (PubMed PMID 41406444) (Existence + topline non-inferiority verified July 2026; exact CI/p-values sit behind the NEJM paywall — confirm the precise stats off the NEJM tables before quoting them as hard numbers.) The obesity CV-outcomes trial (SURMOUNT-MMO) is not expected until 2027.

FDA and U.S. status

Tirzepatide is a fully FDA-approved prescription drug. That is categorically different from the gray-market "research peptides" elsewhere in this library. The 2026 regulatory action targets copies and copycats, not the approved product:

• Shortage resolved December 19, 2024. Once the shortage ended, the legal basis for compounding tirzepatide went away. Deadlines to stop compounding passed in early 2025 (Feb 19 for 503A pharmacies, March 19 for 503B facilities). (FDA)
• As of 2026, compounding "essentially a copy" of tirzepatide is not permitted.
• March 2026 warning letters: the FDA cited online sellers marketing GLP-1 copycats — including tirzepatide and the investigational retatrutide, mazdutide, and cagrilintide — as "research peptides." A "research use only" label does not exempt a product when the page markets weight loss and appetite suppression. (FDA warning letter — Gram Peptides; Venable analysis)
• WADA / sport: Not a prohibited substance.

Risks and warning limits

• Boxed warning — thyroid C-cell tumors: tirzepatide caused dose-dependent thyroid C-cell tumors in rats; human relevance is unknown. Contraindicated with a personal/family history of medullary thyroid carcinoma or MEN 2. (Zepbound FDA label)
• Most common side effects — gastrointestinal: nausea, vomiting, diarrhea, constipation, generally mild-to-moderate and tied to dose escalation.
• Less common but serious: acute pancreatitis (rare, discontinue if suspected), acute gallbladder disease (~0.6% vs. 0% placebo).
• Discontinuation for GI side effects: low single digits in trials (e.g., 3.3–4.3% at higher Zepbound doses vs. 0.5% placebo).
• Body composition: Substantial weight loss includes some lean-mass loss, as with any large calorie deficit. The claim that it is "mostly muscle" is not supported, and the pivotal weight-loss result does not by itself answer how an individual preserves lean mass.

What people are hearing

• Approved-product record: Mounjaro and Zepbound are defined prescription drugs with product-specific labels and manufacturing controls.
• Research-label blur: Material labeled "research tirzepatide" does not inherit the approved products' identity, purity, sterility, concentration, or evidence. FDA warning letters document this copycat marketing.
• Common misconceptions: "Research tirzepatide is the same as Zepbound" (the product has not been authenticated); "microdosing gives the benefits with fewer side effects" (no randomized trial tested that claim; the efficacy figures above come from studied 5, 10, and 15 mg groups); "natural GLP-1 boosters work like this" (nothing over the counter has evidence within an order of magnitude).

What would change this answer

• SURMOUNT-MMO cardiovascular-outcomes readout in obesity (expected 2027).
• Enforcement against GLP-1 copycat sellers through 2026.
• Retatrutide (the investigational triple agonist) — first phase-3 data landed late 2025; an approval decision would reshape the category.

Sources and records

• Jastreboff et al., NEJM 2022 — SURMOUNT-1
• Aronne et al., NEJM 2025 — SURMOUNT-5 (vs. semaglutide)
• SURMOUNT-OSA, NEJM 2024
• Zepbound FDA label (safety, boxed warning)
• FDA — compounding policy as GLP-1 supply stabilized

We do not link to vendors, telehealth prescribers, or supplement sellers.